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The articles contained in this supplement point to the
substantial public health and ﬁnancing implications of
increasing cardiometabolic risk in the US population. In
short, these articles establish in a variety of settings and
populations that obesity can lead to metabolic changes
that, in turn, can lead to the development of dyslipi-
demia, diabetes, and cardiovascular disease (or the
combination of these). The cluster of these cardiomet-
abolic risk factors leads to complications that increase
the expense of treatment and overall economic burden
to the health-care system and workforce. The opening
commentary by Michael Fine rightly points out that the
medical care system in the United States is ill-equipped
to deal with and ﬁnance the expected number of
patients with multiple cardiometabolic risk factors that
will ﬁll the medical ofﬁces, pharmacies, and health-care
institutions in the coming years.
The ﬁrst empirical article by Hollenbeak and col-
leagues uses national data from National Health and
Nutrition Examination Survey (NHANES) to predict
the prevalence of six cardiometabolic risk clusters in
an adult population. Not surprisingly, they ﬁnd that
the cluster of metabolic risk factors that deﬁne the
metabolic syndrome occur in 36% to 40% of the US
population older than 18 years. The article by Caro
et al. extends this analysis and uses a Markov model
to predict the development and cost of diabetes and
cardiovascular disease among the same NHANES
population. These investigators show that increasing
cardiometabolic risk in a population is associated with
increasing disease and cardiovascular events and that
the economic consequence of these complications is
substantial.
The third article by Richard Scranton and col-
leagues uses NHANES data and a simple demographic
model to predict the prevalence of cardiometabolic
risk factors in two large cohort studies—the Athero-
sclerosis Risk in Communities and the Framingham
Offspring Study. They ﬁnd results that are similar to
those of Hollenbeak and conclude that prevalence of
cardiometabolic risk estimation in health plan popula-
tions can be achieved using simple demographic
models calibrated on national data. The article by
Finkelstein et al. uses data from the Medical Expend-
iture Panel Survey (2001–03) to investigate the age-
related impact of obesity on diabetes and dyslipidemia
prevalence and cost. Using these longitudinal data,
these investigators show the expected relationship
between increasing age in obese patients and the
increased prevalence of diabetes and dyslipidemia.
With increasing implementation of electronic health
records, researchers and health policy decision-makers
will be able to combine clinical data with medical
claims ﬁles to create more robust analyses of disease
and economic burden. Brixner and coauthors use a
large medical records database to identify patients with
clinical indicators of cardiometabolic risk. Consistent
with other articles in this supplement, Brixner et al.
ﬁnd close to 37% of patients in the medical records
database have cardiometabolic risk factors that would
support the diagnosis of metabolic syndrome.
The remaining articles by Fitch et al. and Sullivan
et al. highlight the impact that cardiometabolic disease
has on working age populations and the employers
who ﬁnance much of the US health-care system. Both
articles show that, left unchecked, the onslaught of
obesity and cardiometabolic disease will substantially
increase the cost of health care for employers and will
negatively impact work force participation.
When taken together, the collection of articles in
this supplement is a poignant and timely reminder of
the coming epidemic of obesity and cardiometabolic
disease and their attendant impact on public health
and the ﬁnancing of health care in the United States. As
many of the authors of this collection point out, there
are steps that can and should be taken now to reduce
the risk of obesity and other cardiometabolic risk fac-
tors in the population. In particular, Dr Fine provides
some advice for payers at the end of his commentary:
“A blanket exclusion of weight reduction services and
medications may no longer be in the best interest of
managed care organizations or their members.” I
would add that it may not be in the best interest of
employers or of society at large. All organizations with
an interest in the provision of health care should give
this recommendation careful consideration.
